Corrected QT Interval Prolongation in Hospitalized Pediatric Patients Receiving Methadone.

Pediatr Crit Care Med

Department of Pharmacy Services, University of California, Davis Health, Sacramento, CA.

Published: August 2018

Objectives: Methadone is often used in pediatric patients to prevent or treat opioid withdrawal after prolonged sedation. Prolonged corrected QT interval is an important adverse effect of methadone because it can progress to torsades de pointes, a potentially fatal dysrhythmia. The prevalence of corrected QT interval prolongation and contributing risk factors are not well defined in hospitalized pediatric patients receiving methadone. The study purpose was to identify the frequency and risk factors of corrected QT interval prolongation in hospitalized pediatric patients receiving methadone.

Design: Retrospective cohort study.

Setting: Tertiary academic pediatric hospital, University of California Davis Children's Hospital, Sacramento, CA.

Patients: Cohort of 89 pediatric patients (birth to 18 yr) who received at least one dose of methadone while hospitalized.

Interventions: Retrospective data over 7.5 years were obtained from the electronic health record.

Measurements And Main Results: From the cohort, 45 patients (50.6%) had documented corrected QT interval prolongation (≥ 450 ms) during the study period. No episodes of torsades de pointes were identified. In univariate analyses, higher maximum methadone doses were associated with a prolonged corrected QT interval (0.98 vs 0.59 mg/kg/d; odds ratio, 2.56; 1.15-5.70). Corrected QT interval prolongation occurred more frequently in patients with cardiac disease (63% vs 41%; p = 0.10). No factors were statistically significant in the multivariate analysis.

Conclusions: In hospitalized pediatric patients receiving methadone, corrected QT interval prolongation was common, but no episodes of torsades de pointes were documented. Risk factors that have been identified in adults were not associated with prolongation in our study population.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086758PMC
http://dx.doi.org/10.1097/PCC.0000000000001601DOI Listing

Publication Analysis

Top Keywords

corrected interval
32
interval prolongation
24
pediatric patients
24
hospitalized pediatric
16
patients receiving
16
receiving methadone
12
torsades pointes
12
risk factors
12
corrected
8
prolongation hospitalized
8

Similar Publications

Background/objectives: Routine screening electrocardiograms (ECGs) prior to starting medications for attention-deficit/hyperactivity disorder (ADHD) remain controversial. This real-world study assessed corrected QT (QTc) interval data from pediatric patients who had a baseline ECG performed prior to initiating treatment with ADHD medications and ≥6 months of clinical follow-up.

Methods: A retrospective chart review of children aged 2-18 years diagnosed with ADHD with/without autism spectrum disorder (ASD) at child neurology clinics in Jordan (June 2019 and June 2021) was performed, and children were prescribed with ADHD medications to manage symptoms.

View Article and Find Full Text PDF

Objectives: The objectives of the study were to obtain the current estimates of cataract surgical coverage (CSC) at varying thresholds of vision and gender variations across districts in diverse Indian populations aged ≥50 years.

Methods: Data collected from the national blindness survey from 31 Indian districts between 2015 and 2019 were analyzed. CSC at varying thresholds of presenting visual acuity <3/60, <6/60, and <6/18 were estimated along with gender variations across districts in population ≥50 years of age.

View Article and Find Full Text PDF

Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respiration as the primary source of energy. In turn, the addition of an inhibitor of mitochondrial respiration to antiangiogenic therapy holds potential to induce synthetic lethality. This study evaluated the mitochondrial inhibitor ME-344 in combination with bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).

View Article and Find Full Text PDF

Efficacy and Safety of Mydriatic Microdrops for Retinopathy of Prematurity Screening: The MyMiROPS Randomized Clinical Trial.

JAMA Ophthalmol

December 2024

Second Department of Ophthalmology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.

Importance: Commercial mydriatics administered in preterm infants during retinopathy of prematurity (ROP) screening have been associated with various cardiorespiratory and gastrointestinal adverse events.

Objective: To examine whether microdrops of a combined mixture of 1.67% phenylephrine and 0.

View Article and Find Full Text PDF

Purpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.

Methods: Retrospective chart review of patients with nAMD previously treated with aflibercept for at least 12 months and subsequently transitioned to ziv-aflibercept between January 1, 2019, and December 31, 2022, for a period of at least 12 months. Participants were identified, and their clinical and imaging information was extracted from our electronic health records system.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!